WuXi XDC Cayman Inc. risk profile
23 Normal where most of the sector sits
Measured 1 September 2026 from L74's filed statements. Recomputed nightly.
23 (Normal), driven by Market expectation at 49, over 5 weighted categories on the MANUFACTURER profile.
What is measured
| Mechanism | Reading | Band | Direction | Driver |
|---|---|---|---|---|
| Market expectation | 49 | Elevated | Worsening | Average daily turnover — $874 |
| Operating pressure | 10 | Contained | Worsening | Costs outgrowing revenue — -9.0 percentage points |
| Cash conversion | 44 | Elevated | Easing | Capital spending against operating cash — 0.71x |
| Leverage and coverage | 5 | Contained | Stable | Current ratio — 2.75x |
| Competitive position | 26 | Normal | Stable | R&D-intensity gap against peers — -15.7 percentage points |
| Concentration | Reads identified supplier spend, customers above the 10% disclosure threshold and revenue by region. No reading is stored for this company. | |||
These are descriptive readings of disclosed mechanisms, not investment advice, and not a prediction. A band says where a measured input sits, never what to do about it or what happens next.
Healthcare companies with a risk reading
Lilly(Eli) & Company 17Johnson & Johnson 37Abbvie Inc 46Roche Holding AG 32Merck & Co Inc 26Novartis AG 25Astrazeneca plc 30AMGEN Inc 33Thermo Fisher Scientific Inc 45Novo Nordisk A/S 23Abbott Laboratories 43Gilead Sciences Inc 31
Financials, valuation and price history for WuXi XDC Cayman Inc.